Cerebral venous sinus thrombosis (CVST) is a relatively rare condition. We present a case of an acute aseptic thrombosis of the sagittal, transverse and sigmoid sinus in a puerperium patient with protein S deficiency. The specifics of the case include high intracranial pressure (ICP) caused by sinus thrombosis with typical symptomatology and bilateral papilloedema, which also manifested in transient bilateral abducens nerve palsy and, consequently, bilateral horizontal diplopia. The recovery of the cranial nerve function occurred 3 to 4 weeks after it was initially reported. Prompt and adequate anticoagulant therapy contributed to the almost complete recanalization of the dural venous sinus thrombosis and a positive outcome of the disease.

The paper describes a clinical case of transient global amnesia (TGA) in a male patient who has experienced prolonged stress at work and at home. The middle-aged man was admitted to hospital disoriented, constantly repeating the same questions. The patient did not remember what had happened that morning before his admission to the hospital. Brain magnetic resonance imaging revealed bilateral punctate hippocampal DWI hyperintensity. The patient has not been observed to have risk factors for cerebrovascular events. Neuropsychological examination has shown that the patient does not have adequate strategies to cope with the sequels of long-term intense stress accompanied with emotion suppression. The described case confirms that psychological instability may be one of the precipitating factors for TGA.

Razvoj medicine produžio je ljudski životni vijek, ali povećanjem udjela starogstanovništva raste i incidencija neurodegenerativnih bolesti kao što je Alzheimerova bolest. Donedavno je jedina opcija za liječenje Alzheimerove bolesti bila simptomatska terapija u obliku inhibitora kolinesteraze (rivastigmin, donepezil, galantamin) ili antagonista NMDA receptora (memantin). Pokušaji pronalaska potencijalne terapije koja ne ublažava samo kliničku sliku, već može i usporiti ili potpuno zaustaviti progresiju neurološkog i kognitivnog propadanja, usmjereni su na dvije osnovne morfološke karakteristike bolesti – amiloidne plakove i hiperfosforilirane tau neurofibrilarne snopiće, zbog čega se naziva antiamiloidnom i antitau terapijom. Taj se terapijski pristup temelji na inhibiciji sinteze beta-amiloida ili proteina tau, sprječavanju njihova taloženja u agregate ili uklanjanju nastalih patoloških oblika primjenom specifičnih protutijela. Jedan takav lijek, aducunumab (originalno ime Aduhelm), nedavno je odobrio FDA za liječenje blage Alzheimerove bolesti.

No abstract

No abstract